Andrew Garfoot
Senior Scientist II Invenra
Seminars
Wednesday 16th September 2026
From Bi- to Trispecific Antibodies: Reimagining the Next Generation of ADCs
9:30 am
- Bi- and Tri-specific matrix screening rapidly identifies optimal antibody pairings
- B-Body bispecific and T-Body trispecific antibodies exhibited good killing from in vitro ADC assays across a diverse set of breast cancer cell lines
- Multi-target ADCs demonstrate broader and more durable tumor control in vivo, including in drug-resistant cell populations that evade monospecific therapy
